Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266

Watchlist Manager
Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Watchlist
Price: 64.04 CNY -4.28% Market Closed
Market Cap: 17B CNY
Have any thoughts about
Suzhou Zelgen Biopharmaceuticals Co Ltd?
Write Note

EV/FCFF
Enterprise Value to FCFF

-226.1
Current
-27.6
Median
3.6
Industry
Lower than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-226.1
=
Enterprise Value
15.5B CNY
/
FCFF
-68.7m CNY
All Countries
All Countries
Close
 
CN
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Average EV/FCFF: 30.6
Negative Multiple: -226.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -238 717.7
US
Abbvie Inc
NYSE:ABBV
23.3
US
Amgen Inc
NASDAQ:AMGN
32.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -80.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -469.9
AU
CSL Ltd
ASX:CSL
64.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.7
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.2

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 201,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.